We report an unusual case of AML, in which the patient showed extramedullary relapse in the pleural fluid and the skin without bone marrow recurrence even 3 years after allogeneic BMT. On examination of the pleural effusion and the skin, which relapsed 31 months and 40 months, respectively, after BMT, we found that most of cells were as the XY-type recipient by quantitative X/Y FISH (fluorescence in situ hybridization). However, 100% of the bone marrow cells remained XX-type donor cells. In the present case, we believe that the graft-versus-leukemia (GVL) response in the extramedullary site was not so effective as that in the bone marrow, where it remains effective. Bone Marrow Transplantation (2002) 30, 57-59. doi: 10.1038/sj.bmt.1703572 Keywords: extramedullary relapse; allogeneic BMT; quantitative X/Y FISH Extramedullary relapse is a recurrence of leukemia in sites other than the bone marrow. It is known to recur 'isolated' without recurrence in the bone marrow. Since the introduction of bone marrow transplantation (BMT) for the treatment of leukemia, extramedullary relapse is often reported after allogeneic BMT in patients with acute myeloid leukemia (AML). The frequent sites of recurrence are the central nervous system (CNS) and the skin (in the form of leukemia cutis), although it rarely occurs in other sites. However, isolated extramedullary relapse is especially rare without recurrence in bone marrow. 1 We report an unusual case of extramedullary relapse in the pleura and the skin, with no evidence of bone marrow recurrence at death, some 40 months after allogeneic BMT.
Extramedullary relapse is a recurrence of leukemia in sites other than the bone marrow. It is known to recur 'isolated' without recurrence in the bone marrow. Since the introduction of bone marrow transplantation (BMT) for the treatment of leukemia, extramedullary relapse is often reported after allogeneic BMT in patients with acute myeloid leukemia (AML). The frequent sites of recurrence are the central nervous system (CNS) and the skin (in the form of leukemia cutis), although it rarely occurs in other sites. However, isolated extramedullary relapse is especially rare without recurrence in bone marrow. 1 We report an unusual case of extramedullary relapse in the pleura and the skin, with no evidence of bone marrow recurrence at death, some 40 months after allogeneic BMT. 
Case report
The patient was a 41-year-old man having no special past medical history. At the time of hospitalization, the patient appeared chronically ill with a blood pressure of 110/80 mmHg, a pulse rate of 120/min, a respiration rate of 22/min and a body temperature of 37.5°C. He had slightly pale conjunctivae and palpable liver and spleen (each 4 cm). A blood cell count revealed a hemoglobin level of 10.8 g/dl, the white blood cell count was 58.2 ϫ 10 9 /l and the number of platelets was 30 ϫ 10 9 /l. Large myeloblasts with relatively large N/C (nuclear/cytoplasmic) ratio were present at up to 61% in the differential count of peripheral blood cells. Bone marrow sections showed a cellularity of nearly 100% and a diffuse infiltration of myeloblasts. The blasts accounted for up to 46% of the bone marrow nucleated cells and were positive for CD33, CD13, HLA-DR, CD7 and CD34 by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA). BCR/ABL and PML/RARA rearrangement by RT-PCR were negative. Conventional cytogenetics revealed a normal karyotype of 46,XY [20] . A diagnosis of FAB classification, M2 was made (Table 1) .
After induction chemotherapy, the patient showed complete remission and underwent bone marrow transplantation from his HLA-identical sister. The conditioning regimen used was busulfan and cyclophosphamide. The patient was treated with prednisolone and cyclosporin due to chronic graft-versus-host disease (GVHD) according to a liver biopsy performed 8 months after transplantation. Thirtyone months after allogeneic BMT, dyspnea developed and he was hospitalized for pleural effusion evaluation. At the time of hospitalization, a blood cell count showed a hemoglobin level of 11.9 g/dl, a white blood cell count of 5.0 ± 10 9 /l, and a platelet count of 141 ± 10 9 /l. On bone marrow examination, blasts accounted for up to 0.4% of bone marrow nucleated cells. X/Y fluorescence in situ hybridization (FISH) showed that the remaining recipient cells were 0.0%, suggesting complete chimerism, which was supported by the result of conventional cytogenetic study (46, XX[20] ). Thus, complete replacement by donor cells was confirmed in the bone marrow. However, the examination of pleural fluid showed exudates (WBCs Ͼ1.0 ϫ 10 9 /l, RBCs Ͼ1.0 ϫ 10 9 /l, blasts 98%, lymphocytes 18%, PMNs 2%, protein 2.318 mg/dl, glucose 54 mg/dl, LDH 113 mg/dl) and the leukemic blasts were positive for mye- revealed a 46,XY [5] (Table 1) . FISH for the AML1/ETO rearrangement, the MLL rearrangement and inv(16), which are known to occur frequently in granulocytic sarcoma was performed retrospectively on malignant cells of pleural fluid and mononuclear cells of the bone marrow; the results were all negative. The patient was discharged when his symptoms improved after chemotherapy. The patient later visited the hospital about 1 year after this discharge due to generalized skin lesions. A bone marrow study revealed continued remission in the bone marrow, but leukemia cutis was determined with skin biopsy. On microscopy, infiltration of atypical myeloid precursor cells was observed in the dermis, especially in perivascular areas. XY-type recipient cells were also confirmed with X/Y FISH done on the same lesion with paraffin blocks (Figure 1d ). The patient died of septicemia while undergoing chemotherapy; donor lymphocyte infusion was scheduled but could not be performed.
Discussion
Isolated extramedullary relapse in AML patients, excluding CNS relapse, after BMT is rare, and is detected in 0.65% of those with AML (30 patients in 3071). 1 It has been reported that recurrence in the bone marrow occurs within 1 to 12 months of the emergence of isolated extramedullary relapse and the average survival is 10 months.
1,2
The main sites of extramedullary recurrence except CNS and skin are the neck, body cavity, sacral area, spine, limbs, nasopharynx, paranasal sinusoid, bladder, perineum, breast, testis, chest wall, stomach, peritoneal cavity, and pleural cavity. 1, 3 Predisposing factors of isolated extramedullary relapse in leukemia are known to be the delayed diagnosis of leukemia, chromosomal aberrations, which include t(8;21), inv(16), MLL rearrangement, NCAM (CD56) expression by leukemic cells, the expression of other adhesion molecules, such as CD15, T cell markers, and M4 and M5 by the FAB classification. 3 Adhesion molecules, such as CD56 and CD15 are thought to play an important role in the adhesion of leukemia cells to other interstitial tissues and the frequent expressions of CD56, CD15, and T cell markers in isolated extramedullary relapse occurring in rare sites have been reported. 3 In the present case, no chromosomal aberrations including t(8;21), inv(16) and 11q23 translocation, were present. Although the presence of CD56 and CD15 expression could not be determined, the T cell marker CD7 was expressed.
Possible mechanisms of extramedullary relapse without recurrence in the bone marrow have been suggested. One hypothesis is that recurrence occurs in sites that could be inaccessible to chemotherapy or the GVL effect, such as in the central nervous system, which is a general site of extramedullary relapse. In those sites, the effect of anti-cancer drugs or immune effector cells of the patient or donor could be much diminished due to the presence of a barrier, or there may exist microenvironments in which immune cells or cytokines cannot function effectively against malignant cells. Another hypothesis is that the anti-tumor effect of GVL and of the immune surveillance system is not as effective in extramedullary sites as they are in bone marrow, and thus extramedullary relapse occurs. 4 In other words, the anti-tumor effect of activated cytotoxic T lymphocytes can be relatively strong in the hemopoietic tissues. However, the mobilization of activated T lymphocytes might be delayed or activated T lymphocytes might be inhibited at the site of extramedullary relapse.
Isolated extramedullary relapse is usually accompanied by bone marrow recurrence in patients with AML within 1 year Bone Marrow Transplantation of allogeneic BMT, and is known to be a very poor prognostic factor. 1, 5 In the present study, the duration of survival was approximately 10 months after extramedullary relapse. However, long-term survival with a favorable clinical course after localized radiation therapy has been reported despite repeated extramedullary relapse without bone marrow infiltration. 6 Recently, extramedullary relapse was found not to decrease survival times in pediatric patients with t(8;21). 7 Thus, we believe that isolated extramedullary relapse may not an independent factor of poor prognosis. The fact that bone marrow is in molecular genetic remission in patients with isolated extramedullary relapses suggests that the GVH effect remains, at least in bone marrow. This observation suggests that a more significant treatment effect could be expected in patients with isolated extramedullary relapse, as opposed to those with recurrence in the bone marrow, by developing a treatment that enhances the GVH effect in the extramedullary sites.
The case here described is unusual, as it showed extramedullary relapse in the pleura and skin, with no evidence of bone marrow recurrence until death 40 months after the allogeneic BMT. To exclude the possibility of donor origin malignancy, we performed quantitative X/Y FISH in bone marrow, pleural fluid and skin, confirming the recurrence of leukemia of recipient origin in a patient with acute myeloid leukemia.
